Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19
March 3, 2025 11:47 AM ESTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL)
The analyst comments "Monday before Market Open, Ocular Therapeutix reported 4Q24 results. Management hosted a call to discuss progress. The company reported $17.1M in total revenue vs. our estimated $17.8M and diluted EPS of $(0.29) vs. our projected $(0.26). Revenues... More
Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
March 3, 2025 7:10 AM ESTOcular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.04 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $17.08 million versus the consensus estimate of $17.21 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
... More